The Cystitis drugs in development market research report provides comprehensive information on the therapeutics under development for Cystitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cystitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cystitis and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Cystitis by 14 companies/universities/institutes. The top development phase for Cystitis is preclinical with six drugs in that stage. The Cystitis pipeline has 14 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Cystitis pipeline products market are: Profem, AlloVir and Ixaltis.
The key targets in the Cystitis pipeline products market include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16), 16S Ribosomal RNA (16S rRNA), and Gamma-Aminobutyric Acid Receptor Subunit Alpha 4 (GABA(A) Receptor Subunit Alpha 4 or GABRA4).
The key mechanisms of action in the Cystitis pipeline product include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Inhibitor with one drug in Phase II. The Cystitis pipeline products include 13 routes of administration with the top ROA being Oral and three key molecule types in the Cystitis pipeline products market including Small Molecule, and Cell Therapy.
Cystitis overview
Cystitis is a bacterial infection of the bladder or lower urinary tract. It is caused by germs, usually bacteria that enter the urethra and then the bladder. These bacteria can lead to infection, most commonly in the bladder. Cystitis also may occur as a reaction to certain drugs or radiation therapy. Symptoms from a lower urinary tract infection include pain with urination, frequent urination, and feeling the need to urinate despite having an empty bladder. Symptoms of a kidney infection include fever and flank pain usually in addition to the symptoms of a lower UTI. The mainstay of treatment is antibiotics.
For a complete picture of Cystitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
